BergenBio Fundamentale Forhold (BGBIO)

[TekBot]

BerGenBio ASA - Last day of trading in Subscription Rights

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF
THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH
…

Vis børsmeldingen

THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 7 June 2023: Reference is made to the previous stock exchange
announcements from BerGenBio ASA (the “Company”) regarding the partially
underwritten rights issue of between 1,687,500,000 and 2,500,000,000 new shares
in the Company (the “Offer Shares”), at a subscription price of NOK 0.10 per
Offer Share raising gross proceeds of up to NOK 250 million (the “Rights
Issue”). In addition, the subscribers in the Rights Issue will be allocated one
warrant for every two Offer Shares allocated to them and paid by them in the
Rights Issue.

The trading period in the subscription rights in the Rights Issue (the
“Subscription Rights”) with ticker “BGBIT” expires at close of trading today, 7
June 2023 at 16.30 (CEST).

The subscription period for subscribing for new shares in the Rights Issue (the
“Subscription Period”) expires at 16.30 (CEST) on 13 June 2023. Subscription
Rights that are not used to subscribe for Offer Shares before the expiry of the
Subscription Period, or that are not sold before closed of trading today, 7 June
2023 at 16:30 (CEST), will have no value and will lapse without compensation to
the holder.

For more information, and the complete terms and conditions of the Rights Issue,
please refer to the prospectus dated 26 May 2023 (the “Prospectus”). The
Prospectus, including the subscription form, is, subject to applicable local
securities laws, available at the websites of the Company (www.bergenbio.com),
Carnegie AS (www.carnegie.no/ongoing-prospectuses-and-offerings/) and Arctic
Securities AS (www.arctic.com/secno/en/offerings).

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

For information about the Rights Issue please contact the managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made pursuant to the Prospectus for the Rights Issue
dated 26 May 2023.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the aforementioned Prospectus. Copies of the Prospectus is available from the
Company’s registered office and, subject to certain exceptions, on the websites
of the Company (www.bergenbio.com), (Carnegie www.carnegie.no/ongoing
-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Mandatory notification of trade by Primary Insiders and close associates

Bergen 7 June 2023: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 30 May 2023, regarding the
commencement of the subscription period in the rights issue (the “Rights Issue”)
…

Vis børsmeldingen

and the receipt of subscription rights in the Rights Issue by certain primary
insiders and certain close associates of primary insiders of the Company.

As of this date, 7 June 2023, the Company has been informed that the following
primary insiders and close associates in the Company have exercised their
subscription rights, as set out below:

Anders Tullgren, Chairman of the Board of Directors of the Company, has on 5
June 2023, exercised 1,409,872 subscription rights in the Rights Issue,
entitling Anders Tullgren to be allocated 1,409,872 offer shares in the Rights
Issue at a price per offer share of NOK 0.10, subject to the Rights Issue being
completed.

Svev AS, a company closely associated to Sveinung Hole which is a member of the
Board of Directors of the Company, has on 6 June 2023 exercised 2,000,000
subscription rights in the Rights Issue, entitling Svev AS to be allocated
2,000,000 offer shares in the Rights Issue at a price per offer share of NOK
0.10, subject to the Rights Issue being completed.

As of this date, 7 June 2023, the Company has been informed that the following
primary insiders and close associates in the Company have sold subscription
rights, as set out below:

Sveinung Hole, member of the Board of Directors of the Company, has on 6 June
2023 sold 83,182 subscription rights of his total holding of 83,182 subscription
rights in the Rights Issue.

Svev AS, a company closely associated to Sveinung Hole which is a member of the
Board of Directors of the Company, has on 6 June 2023 sold 945,053 subscription
rights of its total holding of 2,945,053 subscription rights in the Rights
Issue.

Sarsia Seed AS, a company closely associated to Sveinung Hole which is a member
of the Board of Directors of the Company, has on 6 June 2023 sold 44,000,000
subscription rights of its total holding of 59,719,358 subscription rights in
the Rights Issue.

The following primary insiders and close associates in the Company have sold and
purchased shares in the Company, as set out below:

Sveinung Hole, member of the Board of Directors of the Company, has on 6 June
2023 sold 2,950 shares in the Company of his total holding of 2,950 shares in
the Company.

Svev AS, a company closely associated to Sveinung Hole who is a member of the
Board of Directors of the Company, has on 6 June 2023 purchased 2,950 shares in
the Company. In addition, Svev AS has on 6 June 2023 sold 107,394 shares in the
Company of its total holding of 107,394 shares in the Company.

Please see further details about the transactions in the attached forms.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

Kilde

[TekBot]

Mandatory notification of trade by Primary Insiders and close associates

Reference is made to the stock exchange announcement published by BerGenBio ASA
(the “Company”) on 30 May 2023, regarding the commencement of the subscription
period in the rights issue (the “Rights Issue”) and the receipt of subscription
…

Vis børsmeldingen

rights in the Rights Issue by certain primary insiders and certain close
associates of primary insiders of the Company.

Today, the Company has been informed that Martin Olin, CEO of the Company, on 5
June 2023, exercised 1,046,125 subscription rights in the Rights Issue,
entitling Martin Olin to be allocated 1,046,125 offer shares in the Rights Issue
at a price per offer share of NOK 0.10, subject to the Rights Issue being
completed.

Please see further details about the transactions in the attached forms.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA - Last day of the Subscription Period in the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF
THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH
…

Vis børsmeldingen

THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 13 June 2023: Reference is made to the previous stock exchange
announcements from BerGenBio ASA (the “Company”) regarding the partially
underwritten rights issue of between 1,687,500,000 and 2,500,000,000 new shares
in the Company (the “Offer Shares”) at a subscription price per Offer Share of
NOK 0.10, raising gross proceeds of up to NOK 250 million (the “Rights Issue”).
In addition, the subscribers in the Rights Issue will be allocated one warrant
for every two Offer Shares allocated to them and paid by them in the Rights
Issue (the “Warrants”).

The subscription period for the Rights Issue (the “Subscription Period”) expires
today, 13 June 2023 at 16:30 (CEST).

Over-subscription and subscription without Subscription Rights is permitted.

Subscriptions for Offer Shares must be made within the expiry of the
Subscription Period and may either be made through the VPS online subscription
system or by submitting a correctly completed subscription form to Arctic
Securites AS or Carnegie AS (acting as managers for the Rights Issue, the
“Managers”). The Warrants will automatically be subscribed for through delivery
of a correctly completed subscription form prior to the expiry of the
Subscription Period.

Subscription rights that are not used to subscribe for Offer Shares before the
expiry of the Subscription Period will have no value and will lapse without
compensation to the holder.

For more information, and the complete terms and conditions of the Rights Issue,
please refer to the prospectus dated 26 May 2023 (the “Prospectus”). The
Prospectus, including the subscription form, is, subject to applicable local
securities laws, available at the websites of the Company (www.bergenbio.com),
Carnegie AS (www.carnegie.no/ongoing-prospectuses-and-offerings/) and Arctic
Securities AS (www.arctic.com/secno/en/offerings).

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

For information about the Rights Issue and subscription please contact the
managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made pursuant to the Prospectus for the Rights Issue
dated 26 May 2023.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the aforementioned Prospectus. Copies of the Prospectus is available from the
Company’s registered office and, subject to certain exceptions, on the websites
of the Company (www.bergenbio.com), (Carnegie www.carnegie.no/ongoing
-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Mandatory notification of trade by Primary Insiders and close associates

Bergen 13 June 2023: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 30 May 2023, regarding the
commencement of the subscription period in the rights issue (the “Rights Issue”)
…

Vis børsmeldingen

and the receipt of subscription rights in the Rights Issue by certain primary
insiders and certain close associates of primary insiders of the Company.

The Company has been informed that Sarsia Development AS, a company closely
associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA,
on 12 June 2023, exercised 33,131,992 subscription rights in the Rights Issue,
entitling Sarsia Development AS to be allocated 33,131,992 offer shares in the
Rights Issue at a price per offer share of NOK 0.10, subject to the Rights Issue
being completed.

Sarsia Seed AS, a company closely associated to Sveinung Hole, Member of the
Board of Directors of BerGenBio ASA, on 12 June 2023, exercised 8,100,000
subscription rights in the Rights Issue, entitling Sarsia Seed AS to be
allocated 8,100,000 offer shares in the Rights Issue at a price per offer share
of NOK 0.10, subject to the Rights Issue being completed.

Please see further details about the transactions in the attached forms.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA - Preliminary results indicates an oversubscribed Rights Issue of gross NOK 250 million

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF
THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH
…

Vis børsmeldingen

THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 13 June 2023: Reference is made to the previous stock exchange
announcements from BerGenBio ASA (the “Company”) regarding the partially
underwritten rights issue of between 1,687,500,000 and 2,500,000,000 new shares
in the Company (the “Offer Shares”) at a subscription price of NOK 0.10 per
Offer Share (the “Rights Issue”). In addition, the subscribers in the Rights
Issue will be allocated one warrant for every two Offer Shares allocated to them
and paid by them in the Rights Issue (the “Warrants”).

The subscription period for the Rights Issue expired at 16:30 hours (CEST)
today, on 13 June 2023.

Preliminary results indicates that the rights issue was oversubscribed, and the
Company has consequently received subscriptions for the maximum number of
2,500,000,000 Offer Shares and approximately 1,250,000,000 Warrants.

The final allocation of the Offer Shares and the Warrants will take place on 14
June 2023 in accordance with the allocation criteria set out in the Company’s
prospectus dated 26 May 2023 (the “Prospectus”).

The final result of the Rights Issue will be published shortly thereafter, and
letters regarding allocation of the Offer Shares and Warrants and the
corresponding subscription amount to be paid by each subscriber, are expected to
be distributed on 14 June 2023.

The due date for payment of the Offer Shares is 16 June 2023.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Rune Skeie, CFO at BerGenBio
ASA on 13 June 2023 at 20:30 CEST on behalf of the Company.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

For information about the Rights Issue please contact the managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made pursuant to the Prospectus for the Rights Issue
dated 26 May 2023.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the aforementioned Prospectus. Copies of the Prospectus is available from the
Company’s registered office and, subject to certain exceptions, on the websites
of the Company (www.bergenbio.com), (Carnegie www.carnegie.no/ongoing
-prospectuses-and-offerings) and Arctic Securities AS
(www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

Kilde

[TekBot]

BerGenBio ASA - Final results of the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF
THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH
…

Vis børsmeldingen

THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 14 June 2023: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 13 June 2023 regarding the
preliminary results in the partially underwritten rights issue of between
1,687,500,000 and 2,500,000,000 new shares in the Company (the “Offer Shares”)
at a subscription price of NOK 0.10 per Offer Share (the “Rights Issue”). In
addition, the subscribers in the Rights Issue will be allocated one warrant for
every two Offer Shares allocated to them and paid by them in the Rights Issue
(the “Warrants”). The subscription period for the Rights Issue expired at 16:30
hours (CEST) on 13 June 2023.

At the expiry of the subscription period in the Rights Issue, the Company had
received subscriptions for a total of 2,500,000,000 Offer Shares and
1,249,999,644 Warrants.

The final allocation of the Offer Shares in the Rights Issue and the Warrants
has now been completed based on the allocation criteria set out in the Company’s
prospectus dated 26 May 2023 (the “Prospectus”).

The board of directors of the Company has allocated a total of 2,500,000,000
Offer Shares, of which 2,431,608,042 Offer Shares were allocated based on valid
subscriptions from investors with subscription rights and 68,391,958 Offer
Shares were allocated based on valid subscription from investors without
subscription rights. Subscribers with subscription rights have been allocated
their full subscription including oversubscription, and investors without
subscription rights have been allocated 51.8% of their subscription.

Based on the number of Offer Shares allocated (as mentioned above), the Company
has allocated, subject to payment of the relevant Offer Shares, 1,249,999,644
Warrants.

Notifications of allocated Offer Shares and Warrants and the corresponding
subscription amount to be paid by each subscriber are expected to be distributed
today, on 14 June 2023. Payment for the allocated Offer Shares falls due on 16
June 2023 in accordance with the payment procedures described in the Prospectus.
The Warrants are allocated free of charge.

The Offer Shares may not be transferred or traded before they have been fully
paid and the share capital increase pertaining to the Rights Issue has been
registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret). The Warrants may not be transferred or traded before they
have been registered in the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret). It is expected that the share capital increase and the
Warrants will be registered in the Norwegian Register of Business Enterprises on
or about 20 June 2023 and that the Offer Shares and the Warrants will be
delivered to the VPS accounts of the subscribers to whom they are allocated on
or about the next day.

The Offer Shares and the Warrants are expected to be tradable on Oslo Børs from
and including 20 June 2023.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Rune Skeie, CFO at BerGenBio
ASA on 14 June 2023 at 13:30 CEST on behalf of the Company.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

For information about the Rights Issue please contact the managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made pursuant to the Prospectus for the Rights Issue
dated 26 May 2023.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the aforementioned Prospectus. Copies of the Prospectus is available from the
Company’s registered office and, subject to certain exceptions, on the websites
of the Company (www.bergenbio.com), (Carnegie www.carnegie.no/ongoing
-prospectuses-and-offerings) and Arctic Securities AS
www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

Kilde

[E24Bot]

Det er ekstremt stor rasfare i Bergenbio-aksjen

Det er ekstremt stor rasfare i Bergenbio-aksjen

[TekBot]

BerGenBio ASA - Correction of final results of the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE
UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF
THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH
…

Vis børsmeldingen

THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 14 June 2023: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) today 14 June 2023 13:30 CEST
regarding the final results in the partially underwritten rights issue of
2,500,000,000 new shares in the Company (the “Offer Shares”) at a subscription
price of NOK 0.10 per Offer Share (the “Rights Issue”). In addition, the
subscribers in the Rights Issue will be allocated one warrant for every two
Offer Shares allocated to them and paid by them in the Rights Issue (the
“Warrants”).

Allocation of 2,500,000,000 Offer Shares has not changed. Based on the number of
Offer Shares allocated, the Company has adjusted the allocation of Warrants,
subject to payment of the relevant Offer Shares, to 1,249,999,617.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Rune Skeie, CFO at BerGenBio
ASA on 14 June 2023 at 15:20 CEST on behalf of the Company.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

For information about the Rights Issue please contact the managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securities in
any Member State of the European Economic Area, other than Norway, which has
implemented the Prospectus Regulation (EU) (2017/1129, as amended, the
“Prospectus Regulation”) (each, a “Relevant Member State”) will be made pursuant
to an exemption under the Prospectus Regulation, as implemented in that Relevant
Member State, from the requirement to publish a prospectus for offers of
securities. Accordingly any person making or intending to make any offer in that
Relevant Member State of securities which are the subject of the offering
contemplated in this announcement, may only do so in circumstances in which no
obligation arises for the Company or any of the Managers to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus
pursuant to Article 16 of the Prospectus Regulation, in each case, in relation
to such offer.

In the United Kingdom, this announcement is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). This announcement are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Managers are acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their respective affiliates accepts any liability arising
from the use of this announcement. Any offering of the securities referred to in
this announcement will be made pursuant to the Prospectus for the Rights Issue
dated 26 May 2023.

This announcement is an advertisement and is not a prospectus for the purposes
of the Prospectus Regulation. Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the aforementioned Prospectus. Copies of the Prospectus is available from the
Company’s registered office and, subject to certain exceptions, on the websites
of the Company (www.bergenbio.com), (Carnegie www.carnegie.no/ongoing
-prospectuses-and-offerings) and Arctic Securities AS
www.arctic.com/secno/en/offerings).

Each of the Company, the Managers and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

Kilde

[TekBot]

BerGenBio - Disclosure of large shareholding

Reference is made to the previous stock exchange announcement from BerGenBio ASA (the “Company”) on June 14 2023, regarding the final results of the NOK 250 million rights issue. Investinor Direkte AS (“Investinor”) has been allocated 214,431,620 new shares in the rights issue. Following the rights issue, Investinor owns a total of 214,431,620 shares representing 8.28% of the total share capital in the Company following the issuance of the 2,500,000,000 new shares.
…

Vis børsmeldingen

Kilde

[TekBot]

BergenBio ASA - Disclosure of large shareholding

Reference is made to the stock exchange announcement made by BergenBio ASA (“BergenBio”) on 14th of June 2023 regarding the final results of the rights issue (the “Rights Issue”). With reference to the press release at 13:30 where information about 2,500,000,000 new shares are to be issued.

Fjärde AP-fonden (“AP4”) holds 4,487,493 shares in BergenBio, equal to approximately 5.06% of the shares and voting rights currently registered in the Norwegian Business Registry. AP4 did not participate in the Rights Issue and upon registration of the share capital increase pertaining to the Rights Issue, AP4’s holding of shares and voting rights in BergenBio will be reduced to approximately 0,17%. AP4 has no other rights to shares issued by BergenBio.
…

Vis børsmeldingen

This announcement is made in accordance with Section 4-2 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA - Mandatory notification of trade, allocations to primary insiders and close associates in the Rights Issue

Bergen 15 June 2023: Reference is made to previous stock exchange announcements
published by BerGenBio ASA (the “Company”), regarding the partially underwritten
rights issue of between 1,687,500,000 and 2,500,000,000 new shares in the
…

Vis børsmeldingen

Company (the “Offer Shares”) at a subscription price of NOK 0.10 per Offer Share
(the “Rights Issue”). In addition, the subscribers in the Rights Issue will be
allocated one warrant for every two Offer Shares allocated to them and paid by
them in the Rights Issue (the “Warrants”). Reference is further made to the
mandatory notifications of trade on 7 June, 8 June and 13 June 2023. Following
the allocation of Offer Shares and Warrants on 14 June 2023, the following Offer
Shares and Warrants have been allocated to primary insiders and their close
associates:

Nigel McCracken, CSO of the Company, subscribed for 550,000 Offer Shares in the
Rights Issue. McCracken was allocated 285,108 Offer Shares at a price of NOK
0.10 per share and 142 554 Warrants. Following delivery of the Offer Shares,
McCracken’s total ownership in the Company amounts to 285,108 shares.

James Barnes, COO of the Company, subscribed for 500,000 Offer Shares in the
Rights Issue. Barnes was allocated 259,190 Offer Shares at a price of NOK 0.10
per share and 129,595 Warrants. Following delivery of the Offer Shares, Barnes’s
total ownership in the Company amounts to 259,190 shares.

Martin Olin, CEO of the Company, subscribed for 2,000,000 Offer Shares in the
Rights Issue. Olin was allocated 2,000,000 Offer Shares at a price of NOK 0.10
per share and 1,000,000 Warrants. Following delivery of the Offer Shares, Olin’s
total ownership in the Company amounts to 2,037,100 shares.

Rune Skeie, CFO of the Company, subscribed for 500,000 Offer Shares in the
Rights Issue. Skeie was allocated 259,190 Offer Shares at a price of NOK 0.10
per share and 129,595 Warrants. Following delivery of the Offer Shares, Skeie’s
total ownership in the Company amounts to 259,190 shares.

Anders Tullgren, Chairman of the Board of the Company, subscribed for 1,409,820
Offer Shares in the Rights Issue. Tullgren was allocated 1,409,820 Offer Shares
at a price of NOK 0.10 per share and 704,910 Warrants. Following delivery of the
Offer Shares, Tullgren’s total ownership in the Company amounts to 1,459,820
shares.

Svev AS, a company closely associated with and 100% owned by Sveinung Hole,
Board member of the Company, subscribed for 2,000,000 Offer Shares in the Rights
Issue. Svev AS was allocated 2,000,000 Offer Shares at a price of NOK 0.10 per
share and 1,000,000 Warrants. Following delivery of the Offer Shares, Svev’s
total ownership in the Company amounts to 2,000,000 shares.

Sally Bennett, Board member of the Company, subscribed for 607,320 Offer Shares
in the Rights Issue. Bennett was allocated 314,826 Shares at a price of NOK 0.10
per share and 157,413 Warrants. Following delivery of the Offer Shares,
Bennett’s total ownership in the Company amounts to 314,826 shares.

Debra Barker, Board member of the Company, subscribed for 600,000 Offer Shares
in the Rights Issue. Barker was allocated 311,027 Shares at a price of NOK 0.10
per share and 155,513 Warrants. Following delivery of the Offer Shares, Barker’s
total ownership in the Company amounts to 311,027 shares.

Sarsia Develoment AS, a company closely associated with Sveinung Hole, Board
member of the Company, subscribed for 33,500,000 Offer Shares in the Rights
Issue. Sarsia Develoment AS was allocated 33,500,000 Offer Shares at a price of
NOK 0.10 per share and 16,750,000 Warrants. Following delivery of the Offer
Shares, Sarsia Developmen’s total ownership in the Company amounts to 33,675,000
shares.

Sarsia Seed AS, a company closely associated with Sveinung Hole, Board member of
the Company, subscribed for 8,100,000 Offer Shares in the Rights Issue. Sarsia
Seed AS was allocated 8,100,000 Offer Shares at a price of NOK 0.10 per share
and 4,050,000 Warrants. Following delivery of the Offer Shares, Sarsia Seed’s
total ownership in the Company amounts to 8,100,000 shares.

Please see further details about the transactions in the attached forms.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA - Updated timeline for delivery of Offer Shares and Warrants in connection with the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE
AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT
NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.

Bergen 19 June 2023: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 15 June 2023 regarding the final
results in the partially underwritten rights issue of 2,500,000,000 new shares
in the Company (the “Offer Shares”) at a subscription price of NOK 0.10 per
Offer Share (the “Rights Issue”). In addition, the subscribers in the Rights
Issue were allocated a total of 1,249,999,617 warrants (the “Warrants”).

Notifications of allocated Offer Shares and Warrants and the corresponding
subscription amount to be paid by each subscriber were distributed on 14 June
2023, and payment for the allocated Offer Shares fell due on 16 June 2023 in
accordance with the payment procedures described in the prospectus dated 26 May
2023. The Warrants are allocated free of charge.

As of today, 19 June 2023, full payment for all Offer Shares has not yet been
received due to lack of sufficient funds on certain subscribers’ designated bank
accounts. The Offer Shares may not be transferred or traded before all Offer
Shares have been fully paid and the share capital increase pertaining to the
Rights Issue has been registered with the Norwegian Register of Business
Enterprises (Nw. Foretaksregisteret). The Warrants may not be transferred or
traded before they have been registered in the Norwegian Register of Business
Enterprises (Nw. Foretaksregisteret).

It is expected that the share capital increase and the Warrants will be
registered in the Norwegian Register of Business Enterprises on or about 22 June
2023 and that the Offer Shares and the Warrants will be delivered to the VPS
accounts of the subscribers to whom they are allocated on or about the next day.

Subject to the aforementioned, the Offer Shares and the Warrants are expected to
be tradable on Oslo Børs from and including 23 June 2023.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

For information about the Rights Issue please contact the managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. Copies of
this announcement are not being made and may not be distributed or sent into any
jurisdiction in which such distribution would be unlawful or would require

registration or other measures. Any offering of the securities referred to in
this announcement will be made by means of a prospectus approved by the
Financial Supervisory Authority of Norway and published by the Company.
Investors should not subscribe for any securities referred to in this
announcement except on the basis of information contained in the aforementioned
prospectus.

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the “Securities
Act”) or with any securities regulatory authority of any state or other
jurisdiction in the United States and may not be offered, sold, pledged or
otherwise transferred within the United States. The Company does not intend to
register any part of the offering in the United States or to conduct a public
offering of securities in the United States.

In any member state of the European Economic Area (each, an “EEA Member State”),
this communication is only addressed to and is only directed at qualified
investors in that EEA Member State within the meaning of the Prospectus
Regulation, i.e., only to investors who can receive the offer without an
approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means Regulation (EU) 2017/1129 as amended (together with any
applicable implementing measures in any EEA Member State).

This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as “relevant persons”). This communication must not be acted
on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only for
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do

so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “believe”, “expect”, “anticipate”,
“strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believe that these assumptions were reasonable
when made, these assumptions are inherently subject to significant known and
unknown risks, uncertainties, contingencies and other important factors which
are difficult or impossible to predict, and are beyond their control. Actual
events may differ significantly from any anticipated development due to a number
of factors, including without limitation, changes in public sector investment
levels, changes in the general economic, political and market conditions in the
markets in which the Company operates, the Company’s ability to attract, retain
and motivate qualified personnel, changes in the Company’s ability to engage in
commercially acceptable acquisitions and strategic investments, and changes in
laws and regulation and the potential impact of legal proceedings and actions.
Such risks, uncertainties, contingencies and other important factors could cause
actual events to differ materially from the expectations expressed or implied in
this release by such forward-looking statements. The Company does not make any
guarantee that the assumptions underlying the forward-looking statements in this
announcement are free from errors nor does it accept any responsibility for the
future accuracy of the opinions expressed in this announcement or any obligation
to update or revise the statements in this announcement to reflect subsequent
events. You should not place undue reliance on the forward-looking statements in
this announcement.

The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice. The Company does not undertake any obligation to review, update,
confirm, or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this announcement.

Neither the Managers nor any of their affiliates makes any representation as to
the accuracy or completeness of this announcement and none of them accepts any
responsibility for the contents of this announcement or any matters referred to
herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of their affiliates accepts any liability arising from the use
of this announcement.

In connection with the Rights Issue, the Managers and any of their affiliates,
acting as investors for their own accounts, may subscribe for or purchase shares
and in that capacity may retain, purchase, sell, offer to sell or otherwise deal
for their own accounts in such shares and other securities of the Company or
related investments in connection with the Rights Issue or otherwise.
Accordingly, references in any subscription materials to the shares being
issued, offered, subscribed, acquired, placed or otherwise dealt in should be

read as including any issue or offer to, or subscription, acquisition, placing
or dealing by, the Managers and any of their affiliates acting as investors for
their own accounts. The Managers do not intend to disclose the extent of any
such investment or transactions otherwise than in accordance with any legal or
regulatory obligations to do so. The distribution of this announcement and other
information may be restricted by law in certain jurisdictions. Persons into
whose possession this announcement or such other information should come are
required to inform themselves about and to observe any such restrictions.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

Kilde

[Laaarsas]

Nån som vill ge sig på att sammanfatta bolagets resa och kurskollaps lite. Om man skulle hoppa in nu, hur bedömer ni att risk-reward ser ut, och varför?

[Roc]

Min subjektive mening:

Er skrevet ganske mye om selskapet i denne tråden. Min kritikk har vært at de har hatt alt for høy cash burn og for lite gjennomtenkt klinisk utviklingsplan. Jeg mener man ikke har noe tydelig effektsignal fra de kliniske studiene som er gjennomført. Vist noe post hoc på noe som ikke var predefinert. Personlig liker jeg ikke safety profilen på druget heller. Høy risiko for min del.

Kort fortalt: Train crash in slow motion, men helt sikkert mulig å gjøre noen gode trades i aksjen.

[Matadoren]

“Personlig liker jeg ikke safety profilen på druget heller”.

Nå er vel BGB324 utprøvd på mere enn 600 pasienter uten noe noen særlige bemerkninger på safety.

“Jeg mener man ikke har noe tydelig effektsignal fra de kliniske studiene som er gjennomført”

De studiene som er gjennomført er tydelig med effekt på AXL positive, I 1. linje STK11 studien (BGBGC016) som de nå har hentet penger til vil alle pasientene være AXL positive, og rasjonale er at BGB324 vil ha god effekt på denne målgruppen innen NSCLC.

[Roc]

Jeg har mangt en gang kommentert mitt syn på sagetyprofilen til BEM. Den viste klart QT-forlengende effekt i fase 1. Deretter kan du få et greit bilde på safetyprofilen i de to fase 2 covid studiene samt fra respektive protokoller mtp eklusjonskriteriene (EU Solid-Act protokollen er public).

Effekten på STK11 mutasjon ble vist post hoc. Hvis du går til fastlegen og tar 40 ulike blodprøver vil 1-2 av prøvesvarene kunne vise verdien utenfor referanse uten at det virkelig stemmer. At man finner noe post hoc uten å ha trenger ikke å tilsi kausalite.

Tror vi kan konkluder med at vi har litt ulikt syn på caset. Har nå fulgt caset og kommentert på det her konsistent siden 2021.

[TekBot]

BerGenBio Reports First Quarter 2023 Financial Results and Provides Business Update

Bergen, Norway, June 22, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced financial results for the first
…

Vis børsmeldingen

quarter ended March 31, 2023, and provided a business update.

“We recently reported the positive readout of several clinical trials that
strongly validate our strategy to concentrate our efforts on evaluating
bemcentinib to treat Non-Small Cell Lung Cancer patients harboring STK11
mutations,” said Martin Olin, Chief Executive Officer of BerGenBio. “I would
like to thank our shareholders for their support of the recent Rights Issue,
providing gross proceeds of 250M NOK, allowing us to pursue the significant
opportunity in STK11m NSCLC. We look forward to sharing initial data from our
Phase 1a/2b trial in the second half of this year towards unlocking the value of
bemcentinib in NSCLC.”

Clinical Development

Bemcentinib

BerGenBio’s lead compound, bemcentinib, is a potentially first-in-class, oral,
highly selective inhibitor of the receptor tyrosine kinase AXL, which is
expressed and activated in response to oxidative stress, inflammation, hypoxia
and drug treatment, resulting in several deleterious effects in cancer and
severe respiratory infections. Bemcentinib selectively inhibits AXL activation
to prevent the progression of serious diseases through the modulation of
resistance mechanisms and the adaptive immune system.

Bemcentinib is currently being developed in STK11 mutated NSCLC and severe
respiratory infections. Its novel mechanisms of action and primary accumulation
in the lungs uniquely position it to address these severe lung diseases.

Oncology: NSCLC

1L STK11m NSCLC (BGBC016)

The Company announced on March 9, 2023, that the first patient was enrolled in
BGBC016, a global, open-label Phase 1b/2a trial designed to determine the
safety, tolerability and efficacy of bemcentinib in combination with standard of
care treatments in untreated advanced/metastatic non-squamous NSCLC patients
with STK11 mutations and no actionable mutations.

The Phase 1b portion of the study is evaluating the safety and feasibility of
three different doses of bemcentinib in combination with pembrolizumab and
doublet chemotherapy in 1L advanced/metastatic non-squamous NSCLC patients,
regardless of STK11 status. The Phase 2a expansion part will assess the safety
and efficacy of up to two doses of bemcentinib in the same treatment combination
in 1L advanced/metastatic non-squamous NSCLC patients with STK11 mutations.

A significant subgroup comprising approximately 20% (> 30,000 patients in US and
EU5) of non-squamous NSCLC patients harbor STK11 mutations, which are associated
with immunosuppression and poor prognosis with standard treatment in 1L NSCLC.
Data suggests that STK11m NSCLC patients almost universally have AXL expression
and activation in tumors and/or on immune cells, resulting in the development of
drug resistance, immune evasion, and metastases.

The results of the BGBC008 (2L+ NSCLC, bemcentinib in combination with
pembrolizumab) and BGBIL005 (2L+ NSCLC, bemcentinib in combination with
docetaxel) trials provide clinical evidence of the anti-tumor effects of
bemcentinib and its ability to modulate the tumor microenvironment to enhance
the effects of immunotherapy and chemotherapy. We believe this provides strong
support for the ongoing BGBC016 1L NSCLC trial in patients harboring STK11
mutations.

2L+ NSCLC Trial (BGBC008)

InFebruary 2023the Company announced topline data from the Phase 2 BGBC008 2L+
NSCLCtrial and provided additional results from pre-planned analyses after
quarter end on May 15,2023. The trial enrolled 90 evaluable patients who
received at least one prior line of therapy:chemotherapy, immunotherapy or the
combination.

· A clinically meaningful survival benefit and evidence of disease control was
demonstratedwithbemcentinibin combination with pembrolizumab regardless of prior
therapy,providing a median overall survival (mOS) of 13.0 months (95% CI: 10.1,
16.7), medianprogression free survival (mPFS) of 6.2 months (95% CI: 4.6, 9.8),
disease control rate(DCR) of 51.1% (95% CI: 40.3, 61.8) and overall response
rate (ORR) of 11.1% (95% CI: 6.2,18.1).
· A significant (p-value < 0.05) and clinically meaningful improvement
inmOSbased on AXLIHC tumor scores was observed. Patients with AXL score > 5 (46%
of evaluable patients)achieved amOSof 14.8 months (95% CI: 12.4, 29.6) compared
to patients with AXL < 5,who achieved amOSof 9.9 months (95% CI: 6.7, 17.4). In
addition, patients with an AXL >5 had amPFSof 8.7 months (95% CI: 6.0, 14.8)
compared to 4.6 months (95% CI: 2.7, 8.1)for patients with AXL < 5. The ORR for
AXL > 5 was 21.9%.
· The observedmOSwas similar regardless of patient PD-L1 status.
· Treatment withbemcentinibin combination with pembrolizumab was well
-tolerated.
· Pre-planned biomarker analyses of patients in BGBC008 indicate that the
combination ofbemcentinib and pembrolizumab in patients with mutations
associated with pooroutcome with available standard of care therapies, including
STK11, KRAS, KEAP-1 andSMARCA4 mutations, may respond as if they have no
mutations in these genes.

At the 2023 AACR meeting, BerGenBio, its investigators and itscollaborator Merck
announcedfindings indicating benefit frombemcentinibin combination with
pembrolizumab treatment in2L NSCLC patients harboring KEAP1 mutations, which can
result in STK11 loss of function.Thesedata indicate that the relevant patient
populations who may benefit from the addition ofbemcentinibto standard of care
therapies may be broader than STK11m patients alone. Thiswill be further
assessed in the on-going BGBC016 study in 1L STK11m NSCLC patients.

2L+ NSCLC Trial (BGBIL005)

In Q4 2022, we announced that in addition to the encouraging ORR and DCR data
previouslypresented from the Investigator Led Study phase 1b/2a trial in
whichbemcentinibwascombined with docetaxel, the final mPFS of 3.1 months and mOS
of 12.3 months furthersupport the clinical benefit of combiningbemcentinibwith
chemotherapy.

Oncology: Relapsed/Refractory AML/MDS

Following the end of the quarter, the Company held a business update conference
call on May 15,2023, that included the topline results of the Phase 1b/2a
BGBC003 multicenter open-label studyofbemcentinibas a single agent and in
combination with low-dose cytarabine (LDAC) ordecitabine in patients with acute
myeloid leukemia or as a single agent in patients withmyelodysplastic syndrome.

· Two cohorts of patients in BGBC003 were treated withbemcentinibas a single
agent(monotherapy). In Cohort B1, in patients with Relapsed/Refractory (R/R)
AML, (n=11),bemcentinib provided an ORR of 18.2% and a mOS of 18 months. In
Cohort B4, in patientswith relapsed/high risk MDS, bemcentinib monotherapy
provided an ORR of 18.8% with a mOSof 9.2months. The Company believes the mOS
achieved is substantially longer than historicalcomparators in these same
patient populations, providing evidence of single-agent efficacy ofbemcentinib.

· Furthermore,bemcentinibin combination with LDAC appeared to provide
substantial mOSbenefit to patients with R/R AML (n=27) achieving an ORR of 18.5%
and a mOS of 8months.Although these findings are encouraging, the Company has
decided not to further pursueclinical trials in this indication given the change
in standard of care therapies in these patientpopulations.

Oncology: Mesothelioma

The topline results of the investigator led BGBIL011/MiST3 mesothelioma trial
were presentedpost-quarter on June 5, 2023, in an oral presentation at the 2023
American Society of ClinicalOncology (ASCO) meeting in an abstract
titled:Bemcentiniband pembrolizumab in patients withrelapsed mesothelioma:
MiST3, a phaseIIatrial with cellular and molecular correlates of efficacy.

MiST, the Mesothelioma Stratified Therapy umbrella trial, is a British Lung
Foundation fundedstudy dedicated to improving survival outcomes for patients
with mesothelioma.MiST3, the thirdarm of the trial, was designed to assess the
efficacy of AXL/PD-1 inhibition with the combinationofbemcentiniband
pembrolizumab.Key results include:

· 26 patients with relapsed mesothelioma were enrolled inMiST3and all received
at least onedose ofbemcentiniband pembrolizumab.
· The primary endpoint of disease control rate at 12 weeks (DCR12w) was met:
46.2% (90% CI:29.2, 63.4).
· Secondary endpoints included a disease control rate at 24 weeks (DCR24w) of
38.5% (95% CI:20.2, 59.4) and an overall response rate of (ORR) of 15.4% (95%
CI: 4.4, 34.9).
· The combination ofbemcentiniband pembrolizumab was generally safe and well
-tolerated.

Severe Respiratory Infections (SRIs)

The Company believes thatbemcentinibblocks viral entry and replication,
stimulates the innateimmune system, and promotes lung tissue repair positioning
it well for the treatment of severerespiratory infections.

BerGenBioannounced after the quarter on April 25, 2023, that after assessing the
significantdrop in hospitalizations attributed to COVID-19 during the 2022-23
winter season, the EU-SolidActTrial Steering Committee in accordance with the
Company decided to pause the Phase2b trial evaluatingbemcentinibin hospitalized
COVID-19 patients until a potential accelerationin hospitalizations warrant
further evaluation ofbemcentinibin this population. Previously theCompany has
completed two Phase 2 trials withbemcentinibin hospitalized COVID-19
patients,showing promising clinical activity.

Bemcentinibis currently being evaluated in preclinical studies for SRIs causing
Acute RespiratoryDistress Syndrome (ARDS) and initial results are expected
during 2023.

Corporate Activities

Rights Offering

On June 13, 2023, the Company completed a rights issue raising gross proceeds
ofNOK 250m.The proceeds from this offering will be dedicated to the conduct of
BGBC016 in 1L STK11mNSCLC patients, preclinical studies in severe respiratory
infections and forgeneral corporatepurposes.

Focused organizational structure aligned with strategy

Post quarter the Company has taken measures to further reduce its operational
costs includinga significant reduction in workforce and total compensation to
the executive management andthe board of directors. These prudent actions will
reduce total operating expenses by at least30% compared to historic operational
expenses when fully implemented.

Oncology Scientific Advisory Board

In February 2023,BerGenBioannounced the formation of a scientific advisory board
to enhancethe development ofbemcentinibfor the treatment of NSCLC patients with
STK11m, consistingof four world-renowned non-small cell lung cancer experts from
top oncology centers aroundthe globe: Enriqueta Felip, M.D., Ph.D., Head of the
Thoracic Cancer Unit at Valld’HebronUniversity Hospital, Spain; JohnHeymach,
M.D., Ph.D., Chair of Thoracic/Head and NeckMedical Oncology at the MD Anderson
Cancer Center, Texas; Tony Mok, M.D.,BMSc., Professorand Chairman of the
Department of Clinical Oncology at the Chinese University of Hong Kong;and
Solange Peters, M.D., Ph.D., Professor and Head of Medical Oncology and
ThoracicMalignancies at the Department of Oncology at Lausanne University,
Switzerland.

First Quarter 2023 Financial Highlights

(Figures in brackets = same period 2022 unless otherwise stated)

•      Revenue was NOK 0 million (NOK 0 million) for the first quarter.
  

•      Total operating expenses for the first quarter were NOK 72.4 million
  

(NOK 78.6 million)

•      The operating loss for the quarter came to NOK 72.4 million (NOK 78.6
  

million)

•      Cash and cash equivalents amounted to NOK 73.0 million at the end of
  

March 2023 (NOK 150.8 million by end of December 2022). In addition, post
quarter, the Company has secured NOK 250 million in gross proceeds from a rights
issue.

The Company provided a business update 15 May and a presentation hosted by
Arctic Securities and Carnegie 2 June 2023 in connection with the rights issue.
Presentations are available at the Company’s
website. (Presentations - BerGenBio) The company will
not host a webcast in connection with this quarterly update.

The Q1 2023 Financial Report is available at the Company’s
website (https://www.bergenbio.com/investors/financial-reports).

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA - New share capital and warrants registered

Bergen 22 June 2023: Reference is made to the stock exchange announcement by
BerGenBio ASA (the “Company”) on 14 June 2023 regarding the final results of the
partially underwritten rights issue of 2,500,000,000 new shares in the Company
…

Vis børsmeldingen

(the “Offer Shares”) at a subscription price of NOK 0.10 per new share, raising
gross proceeds of NOK 250 million (the “Rights Issue”). In addition, the
subscribers in the Rights Issue were allocated one warrant for every two Offer
Shares allocated to them and paid by them in the Rights Issue (the “Warrants”).
The Rights Issue resulted in the issuance of 1,249,999,617 Warrants.

The Warrants and the share capital increase relating to the Rights Issue is now
registered with the Norwegian Register of Business Enterprises. After this, the
Company’s new registered share capital is NOK 258,866,053.20 divided into
2,588,660,532 shares, each with a nominal value of NOK 0.10.

The Offer Shares and the Warrants are expected to be delivered to investors and
tradable on or about 23 June 2023.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA - Correction, new share capital and warrants registered

Bergen 22 June 2023: Reference is made to the stock exchange announcement by
BerGenBio ASA (the “Company”) on 14 June 2023 regarding the final results of the
partially underwritten rights issue of 2,500,000,000 new shares in the Company
…

Vis børsmeldingen

(the “Offer Shares”) at a subscription price of NOK 0.10 per new share, raising
gross proceeds of NOK 250 million (the “Rights Issue”). In addition, the
subscribers in the Rights Issue were allocated one warrant for every two Offer
Shares allocated to them and paid by them in the Rights Issue (the “Warrants”).
The Rights Issue resulted in the issuance of 1,249,999,617 Warrants.

The Warrants and the share capital increase relating to the Rights Issue is now
registered with the Norwegian Register of Business Enterprises. After this, the
Company’s new registered share capital is NOK 258,866,053.20 divided into
2,588,660,532 shares, each with a nominal value of NOK 0.10.

The Offer Shares and the Warrants are expected to be delivered to investors on
23 June 2023, however trading in the Offer Shares on Oslo Børs with ordinary T+2
settlement may accordingly commence now.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

Kilde